Bolder BioPATH

What Bolder BioPATH does

Bolder BioPATH is a private contract research organization headquartered in Boulder, Colorado, founded in 2019. Per firmographic data, the firm operates with 501 to 1,000 employees and is positioned as a provider of pharmacology and pathology services — disciplines that typically support preclinical drug development, safety assessment, and translational research for pharmaceutical and biotechnology sponsors. The combined pharmacology/pathology offering is the conventional bundling point for a mid-sized preclinical CRO, often enabling integrated study design, in-life execution, and downstream tissue-based readouts under a single program management umbrella.

The firm's business model is consistent with a fee-for-service CRO: project-based engagements, custom study design, and quote-based pricing tied to species, duration, and regulatory requirements. Typical customers for a CRO of this profile are pharmaceutical and biotechnology companies running IND-enabling toxicology, safety pharmacology, DMPK, and histology programs; academic and government clients are also common in this segment. No specific pricing tiers, therapeutic area coverage, facility footprint, client logos, leadership team, or backlog disclosures are surfaced in the input.

A material data caveat applies to this record: the detailed operational blocks provided in the input — covering product catalog, GTM motion, financials ($120.9M Q1 FY26 revenue), funding ($65M new-money commitment in June 2026), the Frost & Sullivan 2022 recognition, and the February 2026 cybersecurity incident — are described in relation to Inotiv, Inc. (NASDAQ: NOTV, West Lafayette, Indiana, inotiv.com). These data are not attached to Bolder BioPATH and should not be treated as Bolder BioPATH's facts absent an explicit corporate relationship. As a result, the descriptions above are bounded strictly to the firmographic identity confirmed for Bolder BioPATH.

Name

Bolder BioPATH

Legal name

Inotiv, Inc.

Website

https://bolderbiopath.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bolder BioPATH is a private, Boulder, Colorado-based contract research organization founded in 2019 with 501–1,000 employees, providing pharmacology and pathology services to pharmaceutical and biotechnology clients.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

DMPK / ADME & Bioanalysis (HLAGAFAC)

akta.pro secondary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Pharmacology services
• Pathology services
• Preclinical research
• Drug discovery
• Contract research

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Inotiv provides contract research services including toxicology studies, DMPK analysis, pathology services, and other nonclinical development services to pharmaceutical, biotech, government, and academic clients. Revenue is generated through project-based contracts with varying durations and scopes.
2. Research Models and Services: Sale of research models (laboratory animals) and related services including genetically engineered models, contract breeding, surgical services, genetic testing, and biospecimen services to life science organizations.
3. Teklad Products: Sale of laboratory animal diets, bedding, and environmental enrichment products under the Teklad brand to research institutions and pharmaceutical companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Bolder BioPATH is a Boulder, Colorado-based contract research organization providing pharmacology and pathology services for drug discovery and development. The firm delivers nonclinical research services including disease pharmacology, drug metabolism and pharmacokinetics (DMPK), bioanalysis, toxicology, histology, and pathology to pharmaceutical and biotechnology companies, government agencies, academia, and life science organizations.

Product overview

Bolder BioPATH operates as a Discovery and Development Contract Research Organization (CRO) offering a comprehensive suite of nonclinical and analytical services organized into three main divisions: Discovery and Translational Sciences (including Disease Pharmacology, DMPK, Bioanalysis, Toxicology, Histology/Pathology, and Consulting), Safety Assessment (covering GLP Toxicology, Pathology, Bioanalysis, and specialized studies like DART and Carcinogenicity), and Research Models and Services (including GEMS, breeding, surgical services, and Teklad brand lab animal diets/bedding/enrichment products). The company also provides software tools (Eusoft Labs LIMS, LabTracks) and specialized services like Digital Pathology and Monoclonal Antibody Production. This platform-plus-services architecture enables pharmaceutical and biotech companies, government agencies, academia, and life science organizations to access end-to-end drug discovery and development support.

Differentiator

Problem solved

Functional benefit

Brands

• Teklad: Laboratory animal diets, bedding, and environmental enrichment products
• Eusoft Labs
• LabTracks
• GEMS
• WelfarePlus

Products and services

• Disease Pharmacology In vitro and in vivo disease pharmacology studies to evaluate compound efficacy and mechanism of action in disease models for pharmaceutical and biotech clients.
• Drug Metabolism and Pharmacokinetics (DMPK) In vitro and in vivo DMPK studies from hit-to-lead through candidate selection, supporting absorption, distribution, metabolism, and excretion characterization for drug discovery programs.
• Discovery Bioanalysis and Biomarkers Bioanalytical services for discovery-phase studies including biomarker analysis and quantification to support early drug discovery programs.
• Cell and Molecular Biology Research services focused on cellular and molecular biology techniques to support drug discovery programs.
• Predictive and Computational Toxicology Computational approaches to predict and assess toxicological properties of compounds prior to in vivo testing.
• Toxicogenomics Genomics-based approach to study toxicological responses and mechanisms, providing molecular insight into compound-induced effects.
• Targeted Proteomics Proteomics services focused on targeted analysis of specific proteins for drug discovery and development.
• Histology and Pathology Tissue processing, histological analysis, and pathology services for discovery and nonclinical development projects.
• Pathology Services Anatomical, clinical, and medical device pathology including immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), stereology, and digital pathology for nonclinical studies.
• Consultative Drug Discovery Programs Expert consulting services for drug discovery programs to support client strategy and study design decisions.
• General Toxicology Safety evaluation studies for drugs, medical devices, and chemicals according to international regulatory standards.
• Exploratory Toxicology Early-stage toxicology studies to evaluate compound safety profiles during lead optimization and candidate selection.
• Genetic Toxicology (GLP and Non-GLP) Genetic toxicology testing services including GLP and non-GLP studies to evaluate genotoxicity of compounds.
• Safety Pharmacology Assessment of drug effects on vital organ systems including cardiovascular, respiratory, and central nervous systems as part of IND-enabling packages.
• Developmental and Reproductive Toxicology (DART) Studies evaluating effects of compounds on development and reproduction to support regulatory submissions.
• Carcinogenicity Studies Long-term rodent studies to assess the carcinogenic potential of compounds for regulatory submissions.
• Bioanalysis: Large Molecule (GLP) GLP-compliant bioanalytical services for large molecule therapeutics, including biologics and antibody-drug conjugates.
• Bioanalysis: Small Molecule (GLP) GLP-compliant bioanalytical services for small molecule therapeutics to support regulatory pharmacokinetic studies.
• Impurities Assessment Evaluation and characterization of impurities in pharmaceutical compounds to support regulatory submissions.
• Digital Pathology Whole slide imaging and AI-driven quantitative image analysis to support drug discovery and development pathology projects.

Quantifiable outcome

• Assays developed for 27 ADC targets for oncology and other therapeutic applications

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves1 record

Direct peers

• Frontage Laboratories: Frontage is a CRO specializing in bioanalytical, DMPK, and preclinical services with similar scale and customer profile to Bolder BioPATH. It is one of the closest mid-sized direct comparables in U.S. preclinical services.
• Inotiv: Inotiv is a publicly traded discovery and development CRO offering a nearly identical service portfolio to Bolder BioPATH — DMPK, bioanalysis, histology, pathology, digital pathology, toxicology, and research models. Most direct comparable for a pharmacology and pathology-focused CRO.
• Altasciences: Altasciences is a mid-sized CRO providing preclinical, clinical, bioanalytical, and manufacturing services. Its preclinical and bioanalytical capabilities overlap directly with Bolder BioPATH's pharmacology and pathology focus.

Broad incumbents

• PPD (Thermo Fisher Scientific): PPD, now part of Thermo Fisher, provides preclinical and clinical CRO services including bioanalytical and safety assessment work that overlaps with Bolder BioPATH's core offerings, particularly through Thermo Fisher's broader life sciences platform.
• Eurofins Scientific: Eurofins is a global testing services group with significant bioanalytical, DMPK, and pharmaceutical product testing capabilities. Its central laboratory and bioanalysis divisions compete directly with Bolder BioPATH's analytical services.
• ICON plc: ICON is a top-5 global CRO with growing preclinical and bioanalytical capabilities alongside its dominant clinical franchise. It competes for early-stage development work and integrated outsourced engagements.
• Labcorp Drug Development (Fortrea): Fortrea (spun from Labcorp) is a large clinical and preclinical CRO offering preclinical toxicology, DMPK, bioanalysis, and central lab services. While broader and more clinically focused, it competes for the same preclinical wallet share.
• WuXi AppTec: WuXi AppTec is one of the largest global CROs with extensive preclinical, DMPK, safety assessment, and bioanalytical capabilities. It competes with Bolder BioPATH for outsourced preclinical work, particularly from biotech sponsors seeking integrated discovery-to-clinical offerings.
• SGS Health Sciences: SGS offers preclinical, clinical, and bioanalytical CRO services with strong capabilities in safety assessment, DMPK, and bioanalysis. It is a relevant competitor in the same preclinical services category as Bolder BioPATH.
• Charles River Laboratories: Charles River is a global, full-service CRO with major capabilities in safety assessment, DMPK, and research models — overlapping significantly with Bolder BioPATH's offering but at much greater scale and with a broader discovery and manufacturing footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/InotivCRO
• Instagraminstagram.com/inotiv_cro
• LinkedInlinkedin.com/company/bolder-biopath-inc-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bolder BioPATH